Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 16;112(5):1735–1745. doi: 10.1111/cas.14867

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Changes in bioluminescence intensity over time after the administration of cisplatin (CDDP) using the lymphatic drug delivery system (LDDS). A, Representative bioluminescence images showing luciferase activity. B, Luciferase activity in the proper axillary lymph node (PALN) normalized to the value at day 0^T. Bioluminescence intensity at day 9^T was significantly lower in the IV(+CDDP) group than in the III or IV groups (two‐way ANOVA and Tukey’s test: ***P <.001, III vs IV[+CDDP]; **P <.01, IV vs IV[+CDDP]). There were no statistically significant differences in the bioluminescence intensity among III(+CDDP), IV(+CDDP), and V(+CDDP) at day 9^T. Data are presented as the mean ± SEM (i.v. III[+CDDP], n = 6; III, n = 6; III[+CDDP], n = 7; IV, n = 6, IV[+CDDP], n = 6; V[+CDDP], n = 4)